Nervous Disorder TRIZ Cases

Selective ERα degradation by tricyclic tetrahydroisoquinoline derivatives aims to preserve anti-estrogen activity while reducing SERM side effects.

Elevated ROCK signaling contributes to neurodegenerative disease; Formula I inhibitors target ROCK1 and ROCK2 to reduce kinase activity and support treatment.

Compounds modulate the Sestrin2-GATOR2 interaction to regulate mTORC1 selectively, addressing the limits of direct therapeutic targeting.

pH-sensitive peptides direct therapeutic compounds into acidic tumor microenvironments, limiting exposure to normal cells and systemic side effects.

Synthetic ATM variants such as ATM SINT address low vector transduction while restoring DNA repair, autophagy, and mitochondrial function.

Targeted Fc mutations enhance acidic-pH FcRn binding and thermal stability while preserving effector functions for longer therapeutic half-life.

Selective 5-HT2A agonism with low 5-HT2B activity addresses psilocybin’s cardiotoxicity through azepinoindole analog design.

A decocted Red Peony, Chuanxiong, Hedysarum, and whole raw fish medicament targets stroke sequelae while reducing reliance on continuous therapy.

Specific muropeptides act as ATP synthase agonists to promote ATP production, stabilize mitochondria, and reduce oxidative stress.

Selective spiro-cyclic amine derivatives target S1P5 receptors to address weak modulation in age-related cognitive decline and dementia.

Structural substitution of cyclic bisbenzyl tetrahydroisoquinolines targets SARS-CoV-2 while reducing cytotoxicity and preserving antiviral activity.

Heterogeneous developing-brain tissue complicates precise NSPC isolation; antibody panels and FACS enrich defined populations for functional study.

Systematic R1, R2, R3, and Ring A substitutions address the need for novel orexin type 2 agonists in narcolepsy treatment.

Active site-specific chaperones stabilize concentrated rhGAA, limiting aggregation while supporting tissue uptake in Pompe therapy.

These aminopyrazine derivatives inhibit PI3K-γ kinase activity, addressing the lack of specific inhibitors for autoimmune, cancer, cardiovascular, and neurodegenerative diseases.

See how autoantigen-specific stimulation expands scarce Tregs 100- to 1,000-fold while retaining potent suppressive activity.

Liquid, water-based probiotics support viable bacterial colonization in the gut, promoting SCFA production and intestinal barrier integrity.

Clemizole and related compounds offer a pharmacological option for reducing seizures when conventional AEDs are inadequate in Dravet syndrome.

R-configured derivatives address limited seizure coverage and sedative side effects while adding neuroprotective activity across neurological disease models.

Combining GSTP, GFAP, UCH-L1, NSE, and related markers addresses false negatives and improves mTBI screening reliability.

Isolated, cyclized IGFBP fragments offer a lower-complexity approach to potential disease-modifying treatment for CNS disorders.

Single-receptor therapies can miss complex immune responses; bispecific domains engage OX40 and another TNF receptor in one agent.

New Formula I compounds and salts target GPR52 to address insufficient efficacy across neurological disorders, including schizophrenia and Parkinson’s disease.

Anionic polymers use electrostatic binding to block Aβ-oligomer interaction with PrPC, addressing inadequate treatments for amyloid-related disorders.

Localized substituent changes target HDAC6 more selectively, addressing off-target toxicity while improving absorption and pharmacokinetic behavior.

Limited cancer immunotherapy responses and resistance are addressed with dimeric compounds that reduce cereblon and enhance T-cell activation.

RIPK3 and MLKL inhibition blocks the necrosis cascade, limiting mitochondrial membrane permeabilization, reactive oxygen species, and inflammatory tissue damage.

Low brain penetration can force higher neurological drug doses; this fusion protein combines BBB transport with Fc-based half-life extension.

Amyloid beta-responsive microglia release therapeutic molecules near pathology, helping reduce Aβ aggregates despite the blood-brain barrier.

Engineered CDR sequences help humanized antibodies distinguish scarce A-beta oligomers from monomers and fibrils while inhibiting aggregation.

This case shows how a cell-penetrating peptide can cross the blood-brain barrier while inhibiting α-synuclein fibrillation.

Phospholipid-coated lipid globules mimic human milk fat structure to support myelination in infants with delayed or at-risk brain development.

Obesity treatments may produce weight loss without correcting inflammation, metabolism, or gut permeability; Akkermansia targets all three dysfunctions.

2-Aminoindan derivatives act on D2/D3 dopamine receptors to discourage binge drinking while allowing alcohol consumption.

Replacing curcumin’s unstable β-dicarbonyl structure with monocarbonyl and chlorine substitution improves stability, solubility, and activity.

Blocking CD300c with an antibody targets neuroinflammation and moves beyond symptom relief for degenerative brain disease.

Small molecules modulate SLC6A19 transport to manage phenylalanine levels, offering an alternative to current PKU therapies.

Atipamezole-based compounds address toxicity and corneal degradation in prolonged local anesthesia while preserving motor function.

Selective ALK5 and BMP inhibition accelerates fibroblast conversion into neuron-like cells without artificial gene transfer.

JNK inhibition in Bergmann glia lowers c-Jun phosphorylation and inflammation, improving Purkinje cell pathology and motor coordination in SCA1 mice.

Mutant bHLH factors reduce inhibitory phosphorylation to improve glial-to-neuron conversion across challenging brain environments.

A linked Aβ and tau polypeptide presents both epitopes to induce antibodies for reducing aggregation in Alzheimer's disease.

Computer-aided design and phage display screening produce IL-2 mutants that favor IL-2Rβγ over IL-2Rα to limit VLS.

AAV vectors encode anti-tau antibodies inside brain cells to curb tau aggregation and distribution in tauopathies.

Codon-optimized SURF1 sequences in rAAV vectors address limited gene delivery for SURF1 deficiency and related disorders.

Current therapies do not fully address GPR55-related disorders; nitrogen-containing heterocycles are developed as potential receptor modulators.

VCP inhibition restores nuclear TDP-43 and FUS localization, extending ALS treatment to patients without disease-causing VCP mutations.

Aminotetraline compounds selectively activate 5-HT2A receptors to pursue mental-health benefits while reducing hallucinogenic side effects.

Limited Aβ therapies can cause vascular side effects; bispecific antibodies target Aβ and neurological-cell receptors to clear plaques and reduce neuroinflammation.

Age-related KCC2 overexpression can drive hyper-inhibitory GABAergic transmission; selective inhibitors restore chloride balance and support memory.